When asked about what it meant when a drug was used on or off label wrt the risks, Prof Giardono said that it is likely (that if applied for) puberty blockers would be given a licence for use in gender dyphoric children/adolescents. She says it is likely it would be approved for that indication but pharma companies may just not have any financial incentive to do so. Also they have a lot of evidence through use. She throws precocious puberty in there as if it was of a similar situation. But it isn’t. Those children then go through puberty at the correct time. When used to prevent puberty at the correct time, there are questions about damage done to an adolescent by interfering with their normal development. Physically, mentally, sexual and reproduction development.
And evidence? I think that particular rock has been looked under, and it may not be quite as present and correct as they would like you to believe.
They smoothly talk a good game, for sure. Now the Cass Report has looked more closely at what exactly has been going on, it is not exactly convincing.